ReviewClinical rheumatology2021

Treatment of rheumatic immune-related adverse events due to cancer immunotherapy with immune checkpoint inhibitors-is it time for a paradigm shift?

Katerina Chatzidionysiou et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.